Abstracts Archive - Page 2195 of 2425 - ACR Meeting Abstracts

Abstract Number: 810 • 2013 ACR/ARHP Annual Meeting
Inducible Bronchus Associated Lymphoid Tissue In The Lung Is Associated With Seropositivity For Rheumatoid Arthritis-Related Autoantibodies In Subjects With and Without Clinically Diagnosed Rheumatoid Arthritis
M. Kristen Demoruelle¹, Adam W. Bagley², Mark C. Parish¹, David E. Heinz³, V. Michael Holers⁴, Carlyne D. Cool⁵ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Pathology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁵University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Data suggest the lung may be a site of RA-related autoantibody (Ab) generation including findings of airways inflammation prior to onset of articular RA…
Abstract Number: 811 • 2013 ACR/ARHP Annual Meeting
Influence Of Smoking On Citrullinated Proteins and Porphyromonas Gingivalis In The Lung: A Priming Site For Autoimmunity In RA
Elena B. Lugli¹, Patrick Venables², Raquel Correia³, Karin Lundberg⁴, Ken Bracke⁵ and Guy Brusselle⁵, ¹University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ²Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ³Kennedy Institute of Rheumatology, Univerity of Oxford, Oxford, United Kingdom, ⁴Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Gent University, Gent, Belgium
Background/Purpose: Anti-citrullinated peptide/protein antibodies (ACPA) may be detected in RA serum more than 10 years before onset of disease, suggesting that the autoimmune response begins…
Abstract Number: 812 • 2013 ACR/ARHP Annual Meeting
Alveolar Bone Loss Is Associated With Disease Activity and ACPA Expression In Rheumatoid Arthritis
Ted R. Mikuls¹, Jeffrey Payne², Fang Yu³, Geoffrey M. Thiele⁴, Shawneen Gonzalez², Jeffrey Markt⁵, Jeremy Sokolove⁶, William H. Robinson⁷, Richard J. Reynolds⁸, Grant W. Cannon⁹, David McGowan¹⁰, Gail S. Kerr¹¹, Robert Redman¹², Andreas M. Reimold¹³, Garth Griffiths¹⁴, Mark Beatty², Marian Schmid², Paul Johnson², Debra Bergman¹⁵, Bartlett C. Hamilton III¹⁶, Alan R. Erickson¹ and James R. O'Dell¹⁷, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Otol-Head and Neck Surgery, University of Nebraska Medical Center, Omaha, NE, ⁶Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ¹⁰Dentistry, George E. Wahlen VA Medical Center, Salt Lake City, UT, ¹¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹²Dentistry, Washington DC VA, Georgetown and Howard University, Washington, DC, ¹³Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁴Dentistry, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁵Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹⁶University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, NE, ¹⁷Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Periodontitis (PD) has been implicated in rheumatoid arthritis (RA) pathogenesis including the expression of anti-citrullinated protein antibody (ACPA). ACPA, in turn, have been shown…
Abstract Number: 813 • 2013 ACR/ARHP Annual Meeting
Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
Eddie James¹, Mary Rieck², Jennifer Pieper³, John Gebe⁴, Betty Yue⁴, Megan Tatum⁵, Charlotta Sandin⁶, Lars Klareskog⁷, Vivianne Malmström⁸ and Jane Buckner⁹, ¹Benaroya Research Institute, Seattle, WA, ²Translational Research Program, Benaroya Research Institute, Seattle, WA, ³Department of Medicine, Karolinska Institutet, Rheumatology Unit, Stockholm, Sweden, ⁴Diabetes Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA,, Seattle, WA
Background/Purpose: Rheumatoid arthritis is thought to be a T cell mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to…
Abstract Number: 814 • 2013 ACR/ARHP Annual Meeting
Results Of a Randomised Controlled Trial Comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome
Laura C. Coates^1,2, Anna R. Moverley^1,2, Lucy McParland³, Sarah Brown³, Howard Collier³, Jennifer Law³, Sarah R. Brown³, Neil Corrigan³, Nuria Navarro-Coy^3,4, Paul Emery^2,5, Philip G. Conaghan^1,2 and Philip S. Helliwell^1,6, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: The aim of this study was to assess the impact of tight control of early psoriatic arthritis (PsA) in a randomised-controlled trial (RCT) using…
Abstract Number: 815 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
Maurizio Cutolo¹, Gary E. Myerson², Roy Fleischmann³, Frédéric Lioté⁴, Federico Díaz-González⁵, Filip Van den Bosch⁶, Helena Marzo-Ortega⁷, Eugen Feist⁸, Kamal Shah⁹, ChiaChi Hu⁹, Randall M. Stevens⁹ and Airi Poder¹⁰, ¹University of Genova, Genova, Italy, ²Arthritis and Rheumatology of Georgia, Atlanta, GA, ³Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Hôpital Universitaire Lariboisière, Paris, France, ⁵Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, United Kingdom, ⁸Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Clinical Research Centre Ltd, Tartu, Estonia
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. PALACE 2 compared the efficacy and safety of APR…
Abstract Number: 816 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Philip J. Mease², Arthur Kavanaugh³, Adewale O. Adebajo⁴, Juan J. Gomez-Reino⁵, Jürgen Wollenhaupt⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³University of California San Diego, San Diego, CA, ⁴Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁵Hospital Clinico Universitario, Santiago, Spain, ⁶Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
Abstract Number: 817 • 2013 ACR/ARHP Annual Meeting
Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
MC Genovese¹, Philip J. Mease², Maria W. Greenwald³, Christopher T. Ritchlin⁴, André Beaulieu⁵, Atul A. Deodhar⁶, Richard Newmark⁷, JingYuan Feng⁸, Ngozi Erondu⁸ and Ajay Nirula⁸, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Desert Medical Advances, Palm Desert, CA, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁵Faculty of Medicine, Laval University, Quebec, QC, Canada, ⁶Oregon Health and Science University, Portland, OR, ⁷Clinical Development, Amgen Inc, Thousand Oaks, CA, ⁸Amgen Inc, Thousand Oaks, CA
Background/Purpose: Psoriasis-associated skin and joint disorders are characterized by ongoing inflammation mediated by similar molecular pathways. IL-17 plays a potential role in the pathogenesis and…
Abstract Number: 818 • 2013 ACR/ARHP Annual Meeting
HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis
Muhammad Haroon¹, Agnes Szentpetery², Phil Gallagher³, Robert Winchester⁴ and Oliver FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Dept of Medicine & Pathology, Columbia University, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton. Little is known about the clinical predictors of sacroiliitis (SI),…
Abstract Number: 819 • 2013 ACR/ARHP Annual Meeting
Low Diagnostic Utility Of Candidate Definitions For a Positive MRI Of The Spine In Axial Spondyloarthritis
Ulrich Weber¹, Veronika Zubler², Zheng Zhao³, Robert GW Lambert⁴, Kaspar Rufibach⁵, Stanley Chan⁶, Susanne Juhl Pedersen⁷, Mikkel Ostergaard⁸ and Walter P. Maksymowych⁹, ¹Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ²Radiology, Balgrist University Hospital, Zurich, Switzerland, ³Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁴Radiology, University of Alberta, Edmonton, AB, Canada, ⁵rePROstat, Basel, Switzerland, ⁶Division of Ophthalmology, University of Alberta, Edmonton, AB, Canada, ⁷Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁹Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: A recent consensus statement based on a systematic literature review by the Assessment of SpondyloArthritis International Society suggested the presence of ≥3 corner inflammatory…
Abstract Number: 820 • 2013 ACR/ARHP Annual Meeting
CC-220: A Clinical Stage Immunomodulatory, Antifibrotic Drug For Systemic Sclerosis
Jörg HW Distler¹, Yongqing Wang², Pawel Zerr³, Katrin Palumbo⁴, Gerald Horan⁵, Peter Schafer⁵ and Bashar Kahaleh⁶, ¹Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Medicine, University of Toledo, Toledo, OH, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Translational Development, Celgene Corporation, Summit, NJ, ⁶Medicine/Rheumatology, University of Toledo, Toledo, OH
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disease in which B cells may play a crucial role in pathogenesis. CC-220 is an immunomodulatory drug…
Abstract Number: 821 • 2013 ACR/ARHP Annual Meeting
Activation Of The Signal Transducer and Activator Of Transcription 3 By Transforming Growth Factor-Beta Promotes Fibroblast Activation and Tissue Fibrosis
Barbora Sumova^1,2, Katrin Palumbo-Zerr³, Clara Dees³, Pawel Zerr³, Oliver Distler⁴, Georg Schett⁵, Ladislav Senolt⁶ and Joerg H. W. Distler³, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Germany, Erlangen, Germany, ²Department of Rheumatology of the First Faculty of Medicine, Institute of Rheumatology and Connective Tissue Research Laboratory, Prague, Czech Republic, ³Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by uncontrolled activation of fibroblasts resulting in tissue fibrosis in which the TGFβ signaling plays a main role. Signal…
Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis
Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…
Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Christian Beyer¹, Jürgen Beer¹, Katrin Palumbo-Zerr¹, Pawel Zerr¹, Alfiya Distler¹, Clara Dees¹, Louis E. Munoz¹, Gerhard Krönke¹, Oliver Distler², Steve Anderson³, Georg A. Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Lexicon Pharmaceuticals Inc., The Woodlands, TX, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
Abstract Number: 824 • 2013 ACR/ARHP Annual Meeting
Bosentan Improves Vascular Abnormalities In Endothelial Cell-Specific Fli1 Knockout Mice By Increasing The DNA Binding Ability Of Fli1 – a Possible Mechanism Explaining The Effect Of Bosentan On Scleroderma Vasculopathy
Kaname Akamata¹, Yoshihide Asano¹, Takashi Taniguchi¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Maria Trojanowska² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].